Consecutive patients (32) with metastatic malignant melanoma were treated with vinblastine, bleomycin and cisplatin (VBD) chemotherapy. There were 29 evaluable patients; complete remission was observed in 3 and partial remission in 5. No patient with visceral metastasis showed objective response. The 10-mo. survival rate of responders was significantly higher than that of nonresponders (57.1% vs. 18.2%, P = 0.01); however, present results do not confirm that VBD is superior to other drug combinations for malignant melanoma.